Kathleen V. Forero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kathleen V. Forero has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Raghad Buqaileh
Department of Pharmacology and Experimental Therapeutics, University of Toledo, Toledo, OH 43614, USA
2 shared publications - Wissam A. AbouAlaiwi
Department of Pharmacology and Experimental Therapeutics, University of Toledo, Toledo, OH 43614, USA
2 shared publications - Clare Sunderman
Department of Pharmacology and Experimental Therapeutics, University of Toledo, Toledo, OH 43614, USA
1 shared publication - Clare Sunderman
University of Toledo, Toledo, OH USA
1 shared publication - Gillian M. Gallagher
Department of Pharmacology and Experimental Therapeutics, University of Toledo, Toledo, OH 43614, USA
1 shared publication - Qasim Alorjani
Department of Pharmacology and Experimental Therapeutics, University of Toledo, Toledo, OH 43614, USA
1 shared publication
Latest Publications
- Open Access
- 17 September 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (9) , 1004
Primary Cilia and Cardiovascular Risk Factors in Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common cause of dementia worldwide due to an aging population. AD is characterized as a progressive neurodegenerative disease that leads to atrophy of brain tissue, causing cognitive deficits. Amyloid beta plaques and neurofibrillary tangles are pathological hallmarks of AD, yet the cause is still highly debated. Many other cardiovascular diseases and vascular manifestations share the same symptoms as patients with AD. In this review, the current understanding of AD is summarized with a brief discussion on how primary cilia dysfunction and impaired nitric oxide (NO) signaling contribute to cardiovascular risk factors, vascular pathology, and cognitive decline in AD. Finally, we highlight primary cilia as a possible therapeutic target and any future directions for treating AD.
- 17 September 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (9) , 1004
Open AccessPrimary Cilia and Cardiovascular Risk Factors in Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common cause of dementia worldwide due to an aging population. AD is characterized as a progressive neurodegenerative disease that leads to atrophy of brain tissue, causing cognitive deficits. Amyloid beta plaques and neurofibrillary tangles are pathological hallmarks of AD, yet the cause is still highly debated. Many other cardiovascular diseases and vascular manifestations share the same symptoms as patients with AD. In this review, the current understanding of AD is summarized with a brief discussion on how primary cilia dysfunction and impaired nitric oxide (NO) signaling contribute to cardiovascular risk factors, vascular pathology, and cognitive decline in AD. Finally, we highlight primary cilia as a possible therapeutic target and any future directions for treating AD.
- Open Access
- 29 July 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (8) , 1137
COVID-19 and Neurological Manifestations
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a newly emerged coronavirus, has sparked a global pandemic with its airborne transmission and ability to infect with asymptomatic patients. The pathophysiology is thought to relate to the binding of angiotensin converting enzyme 2 (ACE2) receptors in the body. These receptors are widely expressed in various body organs such as the lungs, the heart, the gastrointestinal tract (GIT), and the brain. This article reviews the current knowledge on the symptoms of coronavirus disease 2019 (COVID-19), highlighting the neurological symptoms that are associated with COVID-19, and discussing the possible mechanisms for SARS-CoV-2 virus infection in the body.
- 29 July 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (8) , 1137
Open AccessCOVID-19 and Neurological Manifestations
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a newly emerged coronavirus, has sparked a global pandemic with its airborne transmission and ability to infect with asymptomatic patients. The pathophysiology is thought to relate to the binding of angiotensin converting enzyme 2 (ACE2) receptors in the body. These receptors are widely expressed in various body organs such as the lungs, the heart, the gastrointestinal tract (GIT), and the brain. This article reviews the current knowledge on the symptoms of coronavirus disease 2019 (COVID-19), highlighting the neurological symptoms that are associated with COVID-19, and discussing the possible mechanisms for SARS-CoV-2 virus infection in the body.